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Mammalian target of rapamycin
Transient receptor potential melastatin 6Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), is used in treatments for transplantation
and cancer. Rapamycin causes hypomagnesemia, although precisely how has not been examined. Here, we
investigated the effect of rapamycin on the expression of transient receptor potential melastatin 6 (TRPM6), a
Mg2+ channel. Rapamycin and LY-294002, an inhibitor of phosphatidilinositol-3 kinase (PI3K) located
upstream of mTOR, inhibited epidermal growth factor (EGF)-induced expression of the TRPM6 protein
without affecting TRPM7 expression in rat renal NRK-52E epithelial cells. Both rapamycin and LY-294002
decreased EGF-inducedMg2+ inﬂux. U0126, a MEK inhibitor, inhibited EGF-induced increases in c-Fos, p-ERK,
and TRPM6 levels. In contrast, neither rapamycin nor LY-294002 inhibited EGF-induced increases in p-ERK and
c-Fos levels. EGF increased p-Akt level, an effect inhibited by LY-294002 and 1L-6-hydroxymethyl-chiro-inositol2-
[(R)-2-O-methyl-3-O-octadecylcarbonate] (Akt inhibitor). Akt inhibitor decreased TRPM6 level similar to
rapamycin and LY-294002. These results suggest that a PI3K/Akt/mTOR pathway is involved in the regulation of
TRPM6 expression. Rapamycin inhibited the EGF-induced increase in TRPM6 mRNA but did not inhibit human
TRPM6 promoter activity. In the presence of actinomycin D, a transcriptional inhibitor, rapamycin accelerated
the decrease in TRPM6 mRNA. Rapamycin decreased the expression and activity of a luciferase linked with
the 3′-untranslated region of human TRPM6 mRNA. These results suggest that TRPM6 expression is up-
regulated by a PI3K/Akt/mTOR pathway and rapamycin reduces TRPM6 mRNA stability, resulting in a
decrease in the reabsorption of Mg2+.]i, intracellular free magnesium
n; TRPM6, transient receptor
ase
+81 54 264 5773.
.
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Mammalian target of rapamycin (mTOR) plays a key role in the
intracellular signaling pathways involved in cell growth and prolif-
eration. Rapamycin, a speciﬁc inhibitor of mTOR, was initially
developed as an immunosuppressant [1]. mTOR is a downstream
effector of a phosphatidylinositol-3-kinase (PI3K)/Akt pathway.
Hyperactivation or overexpression of the mTOR transduction proto-
oncogenes recognized as Ras, PI3K, Akt, S6K1, and eIF4E has been
shown in various solid tumor malignancies [2]. Therefore, rapamycin
is also used in the treatment of kidney transplant patients with
Kaposi's sarcoma, relapsed malignant glioma, hepatocellular carcino-
ma, and cholangiocellular carcinoma. However, rapamycin causes side
effects such as dyslipidemia, bone marrow suppression, and hypo-
magnesemia [3]. The disturbance of magnesium homeostasis can leadto nephropathy. To prevent or lessen nephropathy, it is important to
clarify the mechanism by which rapamycin causes hypomagnesemia.
The transient receptor potential (TRP) channel superfamily is a
diverse group of cation channels expressed in mammalian cells and
plays important roles in a variety of physiological processes [4,5]. The
melastatin subfamily (TRPM) contains eight distinct members,
TRPM1–TRPM8. TRPM1–5 and TRPM8 are non-selective cation
channels, whereas TRPM6 and TRPM7 show high permeability to
magnesium and calcium [6,7]. In the kidney, TRPM6 mRNA and
protein are expressed in the distal convoluted tubule (DCT) [8]. The
DCT is the main site of active transcellular magnesium reabsorption
along the nephron. Mutations in the TRPM6 gene have been identiﬁed
in patients with hypomagnesemia with secondary hypocalcemia
(HSH) [9,10]. TRPM6 must play an important role in the control of
magnesium homeostasis.
The non-genomic regulation of TRPM6 channel has been well
investigated in enforced expression studies [11]. In contrast, little is
known about how the gene expression of TRPM6 mRNA is regulated.
In isolated recessive renal hypomagnesemia, a mutation in the
epidermal growth factor (EGF) gene was identiﬁed [12]. Immuno-
histochemical and electrophysiological analyses show that the
mutation leads to insufﬁcient activation of TRPM6. The activation of
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involving ERK1/2, phosphatidylinositol 3-kinase (PI3K), and p38 MAP
kinase. We recently reported that EGF increases the expression of
TRPM6 mRNA and protein mediated by the activation of a MEK/ERK/
c-Fos pathway in rat renal epithelial NRK-52E cells [13].
Cyclosporine A (CsA), another immunosuppressant, decreases
TRPM6 expression mediated by a decrease in c-Fos expression [14].
However, it is unknown whether rapamycin affects TRPM6 expression.
In the present study, we found that rapamycin inhibits the EGF-induced
increase in TRPM6 expression without affecting TRPM7 expression in
NRK-52E cells. Rapamycin did not inhibit the promoter activity of
human TRPM6 (hTRPM6). However, it accelerated the decrease in
TRPM6 mRNA in the presence of actinomycin D, a transcriptional
inhibitor. Our ﬁndings indicate that rapamycin reduces TRPM6
expression mediated by a decrease in mRNA stability.
2. Materials and methods
2.1. Materials
EGF was obtained from ProSpec-Tany TechnoGene (Rehovot,
Israel). LY-294002 and U0126 were from Sigma-Aldrich (Saint Louis,
MO, USA). Rapamycin was from LC laboratories (Woburn, MA). Goat
anti-β-actin, rabbit anti-p-Akt, and rabbit anti-p-ERK1/2 antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-
TRPM6 (CHAK2) antibody was from Abgent (San Diego, CA). Rabbit
anti-Akt antibody was from Rockland Immunochemicals (Gilbertsville,
PA). Rabbit anti-ERK1/2 antibody was from Cell Signaling Technology
(Beverly,MA).Mag-fura 2/acetoxymethyl ester (AM)andPluronic F-127
were from Molecular Probes (Eugene, OR). 1L-6-Hydroxymethyl-chiro-
inositol2-[(R)-2-O-methyl-3-O-octadecylcarbonate] (Akt inhibitor) was
from BioVision (Mountain View, CA). All other reagents were of the
highest grade of purity available.
2.2. Cell culture
NRK-52E cells (IFO50480), derived from normal rat renal tubules,
were obtained from the Japanese Collection of Research Biosciences
(Osaka, Japan) and grown in Dulbecco's modiﬁed Eagle's medium
supplemented with 5% fetal calf serum (FCS, HyClone, Logan, UT,
USA), 0.07 mg/ml penicillin G potassium, and 0.14 mg/ml streptomy-
cin sulfate in a humidiﬁed atmosphere containing 5% CO2 at 37 °C.
The cells were cultured for 24 h in the medium without FCS before
experiments.
2.3. Preparation of cell lysate and Western blotting
Cells were scraped into cold PBS and precipitated by centrifugation
at 3000×g for 2 min. They were then lysed in a RIPA buffer containing
150 mM NaCl, 0.5 mM EDTA, 1% Triton X-100, 50 mM Tris–HCl (pH
8.0), a protease inhibitor cocktail (Sigma-Aldrich), and 1 mM
phenylmethylsulfonyl ﬂuoride, and sonicated for 20 s. The aliquot
containing the nuclear fraction was used as a total cell extract. After
centrifugation at 6000×g for 5 min, the supernatant was used as a cell
lysate. The total cell extract and cell lysate were solubilized in a
sample buffer for SDS-polyacrylamide gel electrophoresis. Protein
concentrations were measured using a protein assay kit (Bio-Rad
Laboratories, Hercules, CA) with bovine serum albumin as the
standard. SDS-polyacrylamide gel electrophoresis was carried out as
described previously [15]. In brief, samples (30–60 μg) were applied
to the SDS-polyacrylamide gel. Proteins were blotted onto a PVDF
membrane and incubated with each primary antibody followed by
a peroxidase-conjugated secondary antibody. Finally, the blots
were stained with an ECL Western blotting kit from GE Healthcare
Bio-Science or a LumiGLO Reagent and Peroxide from Cell Signaling
Technology.2.4. Quantitative real-time reverse-transcription PCR (RT-PCR)
Total RNA was isolated from cells using ISOGEN (Nippon gene,
Tokyo, Japan) and oligo-dT-primed in the presence of an M-MLV
Reverse Transcriptase (42 °C for 60 min and heated at 99 °C for 5 min).
Quantitative real-time PCR was performed using SYBR Premix Ex Taq
(Takara Bio, Tokyo, Japan). The reaction conditions were an initial 10-s
denaturation at 95 °C, followed by 40 cycles of ampliﬁcation (5 s of
denaturation at 94 °C and 34 s of annealing and extension at 60 °C). At
the ﬁnal dissociation stage, the reaction conditions were 15 s at 95 °C,
60 s at 60 °C, 15 s at 95 °C, and 15 s at 60 °C. The following primers
were used: rat TRPM6, forward 5′-ACCACCTAAGGCAGATGCAA-3′ and
reverse 5′-CAACTTCATTTGGGCTTCTTG-3′; rat β-actin, forward 5′-
CCAACCGTGAAAAGATGACC-3′ and reverse 5′-CCAGAGGCATACAGG-
GACAG-3′; human luciferase, forward 5′-GCTCAGCAAGGAGGTAGGTG-
3′ and reverse 5′-CCGGGAGCTGCATGTGTCAGAGG-3′. The threshold
cycle (ct) for each PCR product was calculated by the instrument
software, and ct values obtained for TRPM6 were normalized by
subtracting the ct values obtained for β-actin. The resulting Δct values
were then used to calculate the relative change in mRNA expression as
the ratio (R) of mRNA expression for drug treatment/control according
to the equation, R=2−(Δct(drug treatment)−Δct(control)).
2.5. Measurement of the intracellular free Mg2+ concentration ([Mg2+]i)
[Mg2+]i was determined using a Mg2+-sensitive ﬂuorescent dye,
mag-fura 2, as described previously [15]. Cells grown on glass slides
were loaded with mag-fura 2/AM at 37 °C for 20 min and placed in a
glass cuvette. [Mg2+]i was calculated according to the formula of
Grynkiewicz et al. [16]. After the addition of 1 mMMgCl2, the increase
in [Mg2+]i for 10 min was calculated.
2.6. Luciferase reporter assay
The promoter region of the hTRPM6 gene [NC_000009.11] was
subcloned into the pGL4.10(luc2) vector (Promega) upstream of a
luciferase reporter gene [17]. A Renilla construct, pRL-TK vector (Toyobo,
Tokyo, Japan),wasused fornormalizing transfectionefﬁciency. Cellswere
transfected with plasmid DNA using HilyMax (Dojindo Laboratories,
Kumamoto, Japan). After 48 h of transfection, luciferase activity was
assessed using theDual-Glo Luciferase Assay System (Promega,Madison,
WI). EGF,U0126, LY-294002, and rapamycinwere added for theﬁnal 24 h
before the luciferase assay. The luminescence of the Fireﬂy and Renilla
luciferasewasmeasuredwith aMultilabel Counter 1420 ARVOsx (Perkin
Elmer,Wellesley,MA). Relative promoter activity was represented as the
fold-increase compared to the promoterless pGL4.10 vector.
2.7. 3′-Rapid ampliﬁcation of cDNA ends (3′-RACE)
The 3′-RACE analysis was performed using total RNA from human
kidney (Clontech Laboratories, CA, USA) with a 5′/3′ RACE Kit, 2nd
Generation (Roche Applied Science, Mannheim, Germany). DNA was
ampliﬁed using the PCR-anchor primer (5′-GACCACGCGTATC-
GATGTCGAC-3′) and a speciﬁc primer (5′-GAGACGGGTAGAAATTCCC-
CAGAA-3′). The sequence analysis was consigned to Bio Matrix
Research (Chiba, Japan). The RACE products showed that the
transcripts terminated at a site 458 bp downstream of the stop
codon (Supplementary ﬁgure 1). The 3′-untranslated region (3′-UTR)
was subcloned into the pGL4.23(luc2/minP) vector (Promega)
downstream of a luciferase reporter gene (Fig. 6A). The expression
and activity of luciferase were assessed as described above.
2.8. Statistics
Results are presented as the mean±SEM. Differences between
groups were analyzed by one-way analysis of variance, and
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multiple comparison test. Comparisons between two groups were
made using Student's t test. Signiﬁcant differences were assumed at
pb0.05.
3. Results
3.1. Decrease in TRPM6 expression and magnesium inﬂux by rapamycin
and LY-294002
TRPM6 mRNA and protein are expressed in renal epithelial NRK-
52E cells [14]. The activation of receptor tyrosine kinases such as the
EGF receptor and platelet-derived growth factor receptor leads to the
activation of MEK/ERK and PI3K/Akt pathways [18,19]. We recently
reported that EGF increases TRPM6 expression, which is inhibited by
U0126. Here, we found that rapamycin and LY-294002 inhibit the
EGF-induced increase in TRPM6 protein (Fig. 1A and B). In contrast,
these inhibitors did not affect the expression of TRPM7 (Fig. 1C).
Rapamycin and LY-294002 inhibited the EGF-induced elevation in
[Mg2+]i (Fig. 1D). These results suggest a rapamycin- and LY-294002-
sensitive pathway to be involved in the regulation of TRPM6
expression and magnesium inﬂux.
3.2. No cross-talk between the MEK/ERK and PI3K/Akt pathways
We examined whether LY-294002 decreases TRPM6 expression
mediated by the inhibition of a MEK/ERK pathway similar to U0126.
EGF increased TRPM6 and c-Fos expression, and this effect wasFig. 1. Decrease in TRPM6 expression and Mg2+ inﬂux caused by rapamycin and LY-294002
30 min before the addition of EGF. They were then incubated with 10 ng/ml EGF plus LY-294
TRPM7, or β-actin antibody. (B and C) The relative expression of TRPM6 and TRPM7 is repre
using a magnesium-sensitive ﬂuorescent dye, mag-fura 2. After the addition of 1 mM Mg
compared with control. ##Pb0.01 compared with EGF. NS, PN0.05 compared with EGF. n=inhibited by U0126 (Fig. 2A). In contrast, rapamycin and LY-294002
decreased TRPM6 expression but did not affect c-Fos expression. EGF
increased p-ERK1/2 levels, and the increase was inhibited by U0126,
but not by rapamycin or LY-294002 (Fig. 2B). Total ERK1/2 levels were
unaffected by EGF, U0126, rapamycin, and LY-294002. These results
suggest that rapamycin and LY-294002 decrease TRPM6 expression
via a pathway that is independent of ERK1/2. EGF also increased p-Akt
level, and the increase was inhibited by LY-294002, but not by U0126
(Fig. 3A). Therefore, we examined the effect of Akt inhibitor on TRPM6
expression. Akt inhibitor decreased p-Akt and TRPM6 expression
similar to LY-294002 (Fig. 3B). These results indicate that a PI3K/Akt/
mTOR pathway is involved in the up-regulation of TRPM6 expression.
3.3. Decrease in TRPM6 mRNA by U0126, LY-294002, Akt inhibitor, and
rapamycin
The effects of U0126, LY-294002, Akt inhibitor, and rapamycin on
TRPM6 mRNA expression were determined by quantitative RT-PCR.
EGF increased TRPM6 mRNA level about 2-fold, which was inhibited
by U0126, LY-294002, Akt inhibitor, and rapamycin (Fig. 4). β-Actin
mRNA was unaffected by these drugs. These results raise the
possibility that the inhibition of a MEK/ERK pathway or a PI3K/Akt/
mTOR pathway reduces the transcriptional activity of TRPM6.
3.4. Decrease in stability of TRPM6 mRNA by rapamycin
The effects of U0126 and rapamycin on hTRPM6 promoter activity
were examined using the hTRPM6-pGL4.10 vector. U0126 signiﬁcantly. (A) NRK-52E cells were pre-incubated with 25 μM LY-294002 or 5 μM rapamycin for
002 or rapamycin for 24 h. The cell lysate (60 μg) was immunoblotted with anti-TRPM6,
sented as the fold-increase compared to the control level. (D) [Mg2+]i was determined
Cl2 to the bath solution, the increase in [Mg2+]i for 10 min was calculated. **Pb0.01
3–8.
Fig. 2. No effect of rapamycin and LY-294002 on c-Fos and p-ERK1/2 levels. (A) Cells
were pre-incubated with 25 μM U0126, 25 μM LY-294002, or 5 μM rapamycin for
30 min before the addition of EGF. They were then incubated with 10 ng/ml EGF plus
U0126, LY-294002, or rapamycin for 24 h. The cell lysate (60 μg) was immunoblotted
with anti-TRPM6, c-Fos, or β-actin antibody. (B) Cells were incubated with 10 ng/ml
EGF plus U0126, LY-294002, or rapamycin for 15 min. The cell lysate (30 μg) was
immunoblotted with anti-p-ERK1/2 or ERK1/2 antibody.
Fig. 3. Decrease in TRPM6 expression caused by Akt inhibitor. (A) Cells were pre-
incubated with 25 μMU0126 or 25 μMLY-294002 for 30 min before the addition of EGF.
They were then incubated with 10 ng/ml EGF plus U0126 or LY-294002 for 15 min. The
cell lysate (30 μg) was immunoblotted with anti-p-Akt or Akt antibody. (B) Cells were
pre-incubated with 10 μM Akt inhibitor for 30 min before the addition of EGF. They
were then incubated with 10 ng/ml EGF or EGF plus Akt inhibitor for 15 min. The cell
lysate (30 μg) was immunoblotted with anti-p-Akt, Akt, or β-actin antibody. Cells were
incubated with EGF or EGF plus Akt inhibitor for 24 h. The cell lysate (60 μg) was


















1505A. Ikari et al. / Biochimica et Biophysica Acta 1808 (2011) 1502–1508inhibited the EGF-induced luciferase activity, whereas rapamycin did
not (Fig. 5A). The regulation ofmRNA turnover is a crucialmechanism in
the post-transcriptional control of gene expression [20]. To examine the
stability of TRPM6mRNA,we investigated the TRPM6mRNA level in the
presence of actinomycin D, a transcriptional inhibitor. NRK-52E cells
were treated with rapamycin in the presence of EGF and actinomycin D
for 0, 3, 6, and 9 h. The TRPM6 mRNA level decreased in a time-
dependent manner (Fig. 5B). Rapamycin accelerated the decrease,
indicating that it reduces the stability of the mRNA. In contrast, U0126
did not signiﬁcantly change the rate of decrease in TRPM6 mRNA
(Fig. 5C). Furthermore, U0126 did not enhance the effect of rapamycin
on the decrease in TRPM6mRNA. These results indicate that U0126does



















Fig. 4. Decrease in TRPM6mRNA caused by U0126 and inhibitors of the PI3K/Akt/mTOR
pathway. (A) Cells were pre-incubated with 25 μM U0126, 25 μM LY-294 002, 10 μM
Akt inhibitor, or 5 μM rapamycin for 30 min before the addition of EGF. They were then
incubated with 10 ng/ml EGF plus U0126, LY-294002, Akt inhibitor, or rapamycin for
24 h. After the isolation of total RNA from the cells, quantitative RT-PCR was performed
using speciﬁc primers for rat TRPM6 and β-actin. The rat TRPM6 mRNA level was
normalized to the β-actin level and expressed as the fold-increase over the control
value. Data represent the mean±SEM for four experiments. **Pb0.01 compared with
control. ##Pb0.01 compared with EGF.3.5. Effect of 3′-UTR on the expression and stability of luciferase
We examined the effect of the 3′-UTR of hTRPM6 on the stability of
the luc2 reporter gene. 3′-RACE showed that hTRPM6 mRNA contains
a 458-bp 3′-UTR (Supplementary ﬁgure 1). As shown in Fig. 6A, the 3′-
UTR of hTRPM6was inserted into the pGL4.23 vector between the luc2
and SV40 late poly (A) signal sequences. EGF did not affect the mRNA
expression or activity of the luciferase-linked with the 3′-UTR of
hTRPM6, whereas rapamycin signiﬁcantly decreased both (Fig. 6B
and C). Neither EGF nor rapamycin affected the expression or activity
of the luciferase in the mock-transfected cells. These results suggest
that the 3′-UTR of TRPM6 is involved in stabilizing the mRNA and the
stability is decreased by rapamycin.
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Fig. 5. Decrease inmRNA stability of TRPM6 caused by rapamycin. (A) The pGL4.10 vector
containing the hTRPM6 promoter region was co-transfected with the pRL-TK plasmid
vector into cells. After 24 h of transfection, the cells were incubated in the presence and
absence of 10 ng/ml EGF plus 25 μMU0126 or 5 μMrapamycin for 24 h. Relative promoter
activity is represented as the fold increase compared to the promoterless pGL4.10 vector.
(B) Cells were pre-incubated in the absence and presence of 5 μM rapamycin for 30 min.
They were then incubated with 10 μM actinomycin D plus 10 ng/ml EGF in the absence
(open circles) and presence (closed circles) of rapamycin for the periods indicated.
After the isolation of total RNA from the cells, quantitative RT-PCR was performed using
speciﬁc primers for rat TRPM6 and β-actin. The rat TRPM6mRNA level was normalized to
the β-actin level and expressed as the fold-decrease compared to 0 h. (C) Cells were pre-
incubated in the absence and presence of 25 μM U0126, 5 μM rapamycin, or U0126 plus
rapamycin for 30 min. Theywere then incubatedwith 10 μMactinomycin D plus 10 ng/ml
EGF in the absence andpresenceof these inhibitors for 9 h.Data represent themean±SEM
for four experiments. **Pb0.01 comparedwith control. ##Pb0.01 comparedwith EGF. NS,





























































Fig. 6. Reduction in expression and activity of a luciferase linked with the 3′-UTR of
TRPM6 by rapamycin. (A) The 3′-UTR of hTRPM6 was subcloned into pGL4.23 vector at
restriction sites between FseI and XbaI. (B and C) Mock vector (open columns) or the
pGL4.23 vector containing the 3′-UTR of hTRPM6 (closed columns) was co-transfected
with the pRL-TK vector into cells. After 48 h of transfection, the cells were incubated
with 10 μM actinomycin D plus 10 ng/ml EGF in the absence and presence of 5 μM
rapamycin for 6 h. The relative expression (B) and promoter activity (C) of the
luciferase are represented as the fold-increase compared to the control level. Data
represent the mean±SEM for 3–6 experiments. **Pb0.01.
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The hypomagnesemia commonly observed in FK506- or cyclo-
sporine A (CsA)-treated patients has been implicated in nephropathy.Rapamycin has structural similarities with FK506 but suppresses the
immune system via differentmechanisms [21]. Rapamycin also causes
hypomagnesemia similar to FK506 and CsA. These immunosuppres-
sants may inhibit renal reabsorption of Mg2+ because they increase
the urinary excretion of Mg2+. Approximately 80% of the total
concentration of Mg2+ in plasma is ﬁltrated in the glomeruli, and the
majority is subsequently reabsorbed along the nephron. TRPM6 is
distributed in the DCT, which reabsorbs 5–10% of the ﬁltered Mg2+,
and the reabsorption in this segment deﬁnes the ﬁnal urinary Mg2+
concentration. Therefore, a dysfunctional TRPM6 causes hypomagne-
semia [9]. We recently found that CsA reduces TRPM6 expression via a
decrease in c-Fos expression [14]. In contrast, the effect of rapamycin
on TRPM6 expression has not been examined.
Little is known about the regulatory mechanism of TRPM6
expression. In mice, TRPM6 expression is up-regulated in the kidney
and colon by 17β-estradiol and a magnesium-enriched diet, respec-
tively [22]. We reported that the EGF-dependent activation of a MEK/
ERK/c-Fos pathway is involved in the up-regulation of TRPM6
expression in NRK-52E cells [13,17]. Signaling by EGF-like ligands is



















Fig. 7. A schematic model of the regulation of TRPM6 expression. EGF activates MEK/ERK and PI3K/Akt/mTOR pathways in NRK-52E cells. U0126 inhibits the MEK/ERK pathway. LY-
294002, Akt inhibitor, and rapamycin inhibit the PI3K/Akt/mTOR pathway. The inhibition of the MEK/ERK pathway decreases transcriptional activity, whereas that of the PI3K/Akt/
mTOR pathway decreases the stability of TRPM6 mRNA.
1507A. Ikari et al. / Biochimica et Biophysica Acta 1808 (2011) 1502–1508ERK, p38 MAP kinase, JNK, and PI3K pathways. Inhibitors of p38 MAP
kinase and JNK did not affect TRPM6 expression [14]. In the present
study, we found that rapamycin decreases the expression of TRPM6
mRNA and protein.
Several studies show that PI3K inhibitors block the phosphory-
lation of ERK1/2 caused by stimuli such as insulin, PDGF, and EGF
[23–25], suggesting that ERK1/2 are downstream effectors of PI3K
signaling. In contrast, PI3K does not have any effect on the EGF-
induced phosphorylation of ERK1/2 [26]. In NRK-52E cells, EGF
increased p-ERK1/2 and p-Akt levels, effects that were inhibited by
U0126 and LY-294002, respectively (Figs. 2 and 3). These results
suggest that there is no crosstalk between the MEK/ERK and PI3K/
Akt/mTOR pathways. Akt, a downstream target of PI3K, is respon-
sible formany of the biological consequences of PI3K activation [27].
Akt inhibitor blocked the EGF-induced elevation in p-Akt and
TRPM6 levels (Figs. 3 and 4). We suggest that TRPM6 expression is
up-regulated by a PI3K/Akt/mTOR pathway.
The mTOR serine/threonine kinase is the catalytic subunit of two
functionally distinct protein complexes, mTORC1 and mTORC2 [28].
mTORC1 containing Raptor, mLST8/GβL, and PRAS is sensitive to
rapamycin. In contrast, mTORC2 containing Rictor, mLST8/GβL, Sin1,
and Protor is resistant to rapamycin. The EGF-induced increase in TRPM6
expression was inhibited by rapamycin in NRK-52E cells (Fig. 1),
suggesting that TRPM6 expression is regulated by mTROC1. However,
Sarbassov et al. [29] reported that mTORC2 is sensitive to prolonged
rapamycin treatment (for 24 h). We cannot exclude the possibility that
mTROC2 is involved in the regulation of TRPM6 expression, but we
suggest that TRPM6 expression is regulated by mTORC1 because
rapamycin accelerated the decrease in TRPM6mRNAwithin 3 h (Fig. 5B).
The TRPM6 mRNA level was decreased by U0126, LY-294002, Akt
inhibitor, and rapamycin in NRK-52E cells (Fig. 4), suggesting the
transcriptional activity of TRPM6 to be inhibited by these drugs.
However, the luciferase reporter assay showed that U0126 inhibits
TRPM6 promoter activity, whereas rapamycin does not (Fig. 5A). So
far, it has been reported that LY-294002 decreases the stability of α1
collagen type I mRNA [30], cyclin D1 mRNA [31], and formyl peptide
receptor 1 mRNA [32]. It should be noted that rapamycin accelerated
the decrease in TRPM6 mRNA in the presence of actinomycin D
(Fig. 5B and C), suggesting that it reduces the stability of TRPM6
mRNA. The most described RNA element involved in the stability of
short-lived messages is the AU-rich elements (AREs) within the 3′-
UTR [33]. The ARE-containing sequence decreased cyclooxygenase-2mRNA level in human ovarian cancer cells [34] and cytokines mRNA
levels in HeLa-tTA cells [35]. The 3′-UTR of TRPM6 contains AU-rich
region, but the motif is not ﬁtted with the classical motifs. However,
rapamycin decreased the expression and activity of the luciferase
linked with the 3′-UTR of hTRPM6 (Fig. 6). The removal of the 5′-cap
(decapping) permits degradation of mRNA. The decapping activity is
inhibited by the cap-binding protein eIF4E located downstream of
mTOR [36]. We suggest that rapamycin affects the 3′-UTR of TRPM6
and decreases the stability of the mRNA. Further study is needed to
clarify how rapamycin reduces the stability of TRPM6 mRNA.
In conclusion, TRPM6 expression is regulated by two signaling
pathways, MEK/ERK and PI3K/Akt/mTOR (Fig. 7). U0126 decreases
TRPM6 expression by reducing transcriptional activity [17]. In
contrast, rapamycin inhibited the EGF-induced increase in TRPM6
expression and [Mg2+]i by reducing the stability of TRPM6mRNA.We
suggest that a PI3K/Akt/mTOR pathway is involved in regulating the
stability of TRPM6 mRNA. Rapamycin causes hypomagnesemia with
high urinary excretion of magnesium in rats [3]. The decrease in the
stability of TRPM6 mRNA caused by rapamycin may inhibit the
reabsorption of Mg2+ in the kidneys, resulting in hypomagnesemia.
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